Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants
- PMID: 11779098
- DOI: 10.18926/AMO/31997
Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants
Abstract
In the present investigation, we studied the effect of recombinant human erythropoietin (r-HuEPO) on serum malondialdehyde (MDA) as an index of lipid peroxidation, related to iron-catalyzed free radical reaction and erythrocyte superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX) activities in very-low-birth weight (VLBW) infants. Forty premature infants, at gestational ages were less than 33 weeks and birthweights were less than 1,500 g, were enrolled in the study. The study population was randomly divided into 2 groups. Twenty infants in Group 1 (treatment group) were given r-HuEPO, and 20 infants in Group 2 served as the control. r-HuEPO treatment (750 U/kg a week) was initiated on the 10th day of life and continued for 6 weeks. Preterm infants given erythrocyte transfusions during the study were excluded from the results. Serum ferritin and MDA levels, and erythrocyte superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX) activities were analyzed at the end of the first week of life (at the beginning of the study). Subsequently, serum ferritin, and MDA levels were measured at the end of the 3rd and the 6th week. SOD, CAT, and GPX activities in the hemolysate were analyzed at the end of the 4th week. Six infants in the control group and 1 infant in the r-HuEPO group received transfusions through the end of the study, and these infants were excluded from the results. Significantly decreased serum ferritin concentrations were found in the r-HuEPO group compared to those in the control group both at the end of the 3rd and the 6th week (P < 0.05, and P < 0.01, respectively). In addition, serum MDA levels were also significantly reduced in Group 1 compared to control both at the end of the 3rd and the 6th week (P < 0.01 and P < 0.05, respectively). A good correlation was found between serum MDA and ferritin levels in Group 1. When the 2 groups were compared with respect to activities of SOD, CAT, and GPX at the end of the 4th week, no differences were observed. Our findings in this study show that administration of r-HuEPO significantly decreases lipid peroxidation, but does not affect erythrocyte antioxidant enzyme(s) activities in preterm infants. The mechanism responsible for the r-HuEPO-induced decrease in lipid peroxidation may concern inhibition to iron-catalyzed free radical reactions.
Similar articles
-
Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants.Pediatrics. 1995 Jan;95(1):1-8. Pediatrics. 1995. PMID: 7770284 Clinical Trial.
-
Red cell lipid peroxidation and antioxidant system in haemodialysed patients: influence of recombinant human erythropoietin (r-HuEPO) treatment.Int Urol Nephrol. 1998;30(4):507-12. doi: 10.1007/BF02550233. Int Urol Nephrol. 1998. PMID: 9821056
-
Effect of recombinant human erythropoietin on transfusion needs in preterm infants.J Paediatr Child Health. 2001 Aug;37(4):352-8. doi: 10.1046/j.1440-1754.2001.00667.x. J Paediatr Child Health. 2001. PMID: 11532054 Clinical Trial.
-
[Iron supplementation in preterm infants treated with erythropoietin].Arch Pediatr. 1999 Jun;6(6):657-64. doi: 10.1016/s0929-693x(99)80299-1. Arch Pediatr. 1999. PMID: 10394459 Review. French.
-
[Recombinant human erythropoietin in premature infants. Evaluation of a one year experience].Arch Pediatr. 1999 Sep;6(9):944-51. doi: 10.1016/s0929-693x(99)80586-7. Arch Pediatr. 1999. PMID: 10519027 Review. French.
Cited by
-
One-year experience in the retinopathy of prematurity: frequency and risk factors, short-term results and follow-up.Int J Ophthalmol. 2011;4(6):634-40. doi: 10.3980/j.issn.2222-3959.2011.06.12. Epub 2011 Dec 18. Int J Ophthalmol. 2011. PMID: 22553735 Free PMC article.
-
Ferroptosis: A Promising Therapeutic Target for Neonatal Hypoxic-Ischemic Brain Injury.Int J Mol Sci. 2022 Jul 4;23(13):7420. doi: 10.3390/ijms23137420. Int J Mol Sci. 2022. PMID: 35806425 Free PMC article. Review.
-
Protective effects of erythropoietin against cuprizone-induced oxidative stress and demyelination in the mouse corpus callosum.Iran J Basic Med Sci. 2017 Aug;20(8):886-893. doi: 10.22038/IJBMS.2017.9110. Iran J Basic Med Sci. 2017. PMID: 29085580 Free PMC article.
-
Iron therapy for preterm infants.Clin Perinatol. 2009 Mar;36(1):27-42. doi: 10.1016/j.clp.2008.09.013. Clin Perinatol. 2009. PMID: 19161863 Free PMC article.
-
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.BMC Med Genomics. 2009 Jan 8;2:2. doi: 10.1186/1755-8794-2-2. BMC Med Genomics. 2009. PMID: 19133145 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous